We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


Diazyme develops diagnostic reagents using its proprietary enzyme technologies that can be used on most automated che... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Performance of Five Lipoprotein(a) Immunoassays Evaluated

By LabMedica International staff writers
Posted on 06 Apr 2021
Print article
Image: The Diazyme Lipoprotein A assay kit is for the in vitro quantitative determination of Lp(a) concentration in human serum or plasma on Clinical Chemistry Systems (Photo courtesy of Diazyme)
Image: The Diazyme Lipoprotein A assay kit is for the in vitro quantitative determination of Lp(a) concentration in human serum or plasma on Clinical Chemistry Systems (Photo courtesy of Diazyme)
Increased serum Lipoprotein(a) [Lp(a)] is considered an independent, inherited risk factor for atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke. This risk is believed to be due to pro-atherogenic, pro-inflammatory, and pro-thrombotic properties of the Lp(a) particle.

Lp(a) can be measured using a variety of methods, including enzyme linked immunosorbent assays (ELISA), latex-agglutination, immunoturbidimetry/immunonephelometry, electrophoresis, and immunofixation electrophoresis (IFE). A confounding factor is that Lp(a) can be reported in either mass units (mg/dL of the total Lp(a) particle) or molar concentration of particles (nmol/L).

Medical Laboratorians at the ARUP Institute of Clinical and Experimental Pathology (Salt Lake City, UT, USA) and their colleagues used 80 residual serum samples, and specimens from 120 self-reported healthy subjects (61 females/59 males) were also tested in a study. The aim of the study was to evaluate performance characteristic of five different Lp(a) assays using the cobas c501 analyzer (Roche Diagnostics, Indianapolis, IN, USA).

The five assay for Lp(a) used were from: Diazyme (Poway, CA, USA), Kamiya Biomedical Company (Seattle, WA, USA), MedTest Dx (Canton, MI, USA), Randox Laboratories (Crumlin, UK) and Roche Diagnostics, configured to mg/dL units. Assays from Diazyme and Kamiya were also configured using nmol/L units in separate studies. Studies included sensitivity, imprecision, linearity, method comparison, and evaluation of healthy subjects. Imprecision (intra-day, 20 replicates; inter-day, duplicates twice daily for five days) and linearity were evaluated using patient pools. Linearity assessed a minimum of five patient splits spanning the analytical measurement range (AMR).

The scientists reported that all methods met manufacturer claims regarding sensitivity: observed (manufacturer claim): Diazyme, 0.7 mg/dL (1.3 mg/dL); Kamiya, 1.2 mg/dL (5.0 mg/dL); MedTest, 0.2 mg/dL (1.3 mg/dL); Randox, 0.7 mg/dL (3.0 mg/dL); Roche, 0.3 mg/dL (4.0 mg/dL). Lp(a) assays also demonstrated acceptable imprecision and met manufacturers’ claims, with CVs less than 6% in all cases. Imprecision studies demonstrated %CVs ranging from 2.5 – 5.2% for the low pool (average concentration from 7.3 – 12.4 mg/dL); high pool %CVs ranged from 0.8 – 3.0% (average concentrations from (31.5 – 50.2 mg/dL). Linearity was confirmed for all assays. Variation in accuracy was observed when comparing results to an all method average. Lp(s) results were higher in females versus males in self-reported healthy subjects.

The authors concluded that all assays performed according to manufacturer described performance characteristics, although differences were observed across Lp(a) assays tested when compared to an all method average. The study was published on March 24, 2021 in the journal Practical Laboratory Medicine.

Related Links:
ARUP Institute of Clinical and Experimental Pathology
Roche Diagnostics
Kamiya Biomedical Company
MedTest Dx
Randox Laboratories

Gold Supplier
TBI Blood Test
i-STAT TBI Plasma Test
Lateral Flow Test Reader
Silver Supplier
COVID-19 Ag Self Test
OnSite COVID-19 Ag Self Test
Mobile Clinical Chemistry Lab
Statlab Station

Print article


Clinical Chem.

view channel
Image: Illustration is of the Vertical Auto Profile (VAP) Lipid test with clear demarcation of the different lipoprotein classes and subclasses. (Photo courtesy of VAP Diagnostics Laboratory)

Lipoprotein(a) Concentrations Correlate With LDL-C in Diabetic Children

Cardiovascular disease (CVD) is a significant cause of mortality in those with diabetes. Increased apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) have been shown in pediatric patients... Read more

Molecular Diagnostics

view channel
Image: Model of the PD-1 (Programmed cell death protein 1) protein. Only a subset of recurrent glioblastomas respond to anti-PD-1 immunotherapy (Photo courtesy of Wikimedia Commons)

Biomarker Predicts Potential Benefit of Checkpoint Inhibitor Therapy for Brain Cancer Patients

A phosphorylated form of ERK (extracellular signal-regulated kinase) protein has been identified as a biomarker that may be used to predict which brain cancer patients might benefit from checkpoint inhibitor... Read more


view channel
Image: The UniCel DxH 800 Coulter Cellular Analysis System (Photo courtesy of Beckman Coulter)

Monocyte Distribution Width Predicts Sepsis in Critically Ill Patients

Sepsis has been reported as a major cause of increased morbidity, length of stay and mortality among patients hospitalized in Intensive Care Units (ICUs) for any cause. The survival of patients developing... Read more


view channel
Image: Clinical metagenomics (CMg) using nanopore sequencing (Photo courtesy of Oxford Nanopore Technologies)

Same Day Test Identifies Secondary Infections in COVID-19 Patients

The intensive care unit (ICU) is a dynamic environment with frequent staff-patient contact for invasive monitoring, interventions and personal care that together introduce the risk of secondary or nosocomial... Read more


view channel
Image: The Ventana BenchMark Ultra autostainer is for cancer diagnostics with automation and the test menu include IHC, ISH, and FITC tests (Photo courtesy of Ventana Medical System)

Specific Biomarker Investigated for Triple-Negative Breast Cancer Diagnosis

Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression and comprises a heterogeneous... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global HBA1c Laboratory Tests Market Driven by Rise in Diabetic Population

The global HBA1c laboratory tests market is projected to expand at a significant pace over the coming years, driven by an increase in the prevalence of diabetes, rise in prescription rate of HBA1c tests... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.